


Exhibit H



WTS Number: 698305



Request Date: 7/20/11 9:17 AM

Conf Number: 220698

Requester: Timothy Jones

Sterne Kessler Goldstein & Fox
1100 New York Avenue, NW, Suite 900

Washington, DC 20005

RUSH

Company Phone: 202-371-2600

Delivery: Email

Requester Phone: 202-772-8789

Instructions:

Fax: 202-371-2540

Requester Email: Tjones@skgf.com

Send-To Email: Tjones@skgf.com

Reference: 2286.0880000

2.Saib RJ;Howarth PH-Drug Saf 26(12):pgs.863-93,2003

Mad/ a 7D834

An outreach service of the Kurt F. Wendt Library, University of Wisconsin - Madison
Email: wts@engr.wisc.edu | Web: <http://www.wisc.edu/techsearch> | Phone: (608) 262-5917

0114-5916

Requester assumes responsibility for copyright compliance.

Refer Off Campus

Drug SafetyTM

2003, Vol. 26, No. 12 (pp. 829-911)

ISSN: 0114-5916

Leading Articles

Pharmacovigilance of Herbal Medicines
Benefit-Risk Analysis: Proposed Quantitative Approaches

Review Article

Intranasal Antihistamines and Intranasal
Corticosteroids in Allergic Rhinitis

Original Research Article

Adverse Effects of ACE Inhibitors in Heart Failure

PHARMACY LIBRARY
UNIVERSITY OF WISCONSIN

OCT 02 2003

Madison, WI 53705

Available Online

adis
INTERNATIONAL
A Wolters Kluwer Company

AUCKLAND • BARCELONA • BUENOS AIRES • CHESTER • HONG KONG • MADRID • MILAN
MUNICH • OSAKA • PARIS • PARSIPPANY • PHILADELPHIA • ROME • SÃO PAULO • TOKYO

International Editorial Board

F.Y. Aoki, *Winnipeg, MN, Canada*
B. Bannwarth, *Bordeaux, France*
J. Barnes, *London, England*
N.L. Benowitz, *San Francisco, CA, USA*
J-F. Bergmann, *Paris, France*
F.M.C. Besag, *Clapham, England*
N. Buckley, *Woden, ACT, Australia*
P.A. Chyka, *Memphis, TN, USA*
D.M. Coulter, *Dunedin, New Zealand*
R.O. Day, *Sydney, NSW, Australia*
N. Dunn, *Southampton, England*
I.R. Edwards, *Uppsala, Sweden*
A.C.G. Egberts, *Utrecht, The Netherlands*
K. Ghosé, *Dunedin, New Zealand*
L. Howes, *Kogarah, NSW, Australia*
J-R. Laporte, *Barcelona, Spain*
D.H. Lawson, *Glasgow, Scotland*
B.J. Lipworth, *Dundee, Scotland*
T. Litovitz, *Washington, DC, USA*
R. Meyboom, *'s-Hertogenbosch, The Netherlands*
J-L. Montastruc, *Toulouse, France*
M. Moore, *Toronto, ON, Canada*
J. Moseley, *London, England*
G.J. Moyle, *London, England*
C.A. Naranjo, *Toronto, ON, Canada*
P.J. Nicholls, *Cardiff, Wales*
R.I. Ogilvie, *Toronto, ON, Canada*
D.R. Owens, *Penarth, Wales*
S. Shakir, *Southampton, England*
N. Shear, *Toronto, ON, Canada*
D.A. Sica, *Richmond, VA, USA*
O. Spigset, *Trondheim, Norway*
E.P. van Puijenbroek, *'s-Hertogenbosch, The Netherlands*
G.N. Volans, *London, England*
L.V. Wilton, *Southampton, England*
M. Winkler, *Hannover, Germany*
I.C.K. Wong, *London, England*

Aim and Scope: *Drug Safety* advances the rational use of pharmacotherapy by providing a programme of review articles offering guidance for safe and effective drug utilisation and prescribing.

The Journal includes:

- Leading/current opinion articles providing an overview of contentious or emerging issues
- Definitive reviews on the epidemiology, clinical features, prevention and management of adverse effects of an individual drug or drug class when given at therapeutic dosages or following overdose
- Benefit-risk assessments providing an in-depth review of adverse effects and efficacy data for a drug in a specific disease to place the benefit-risk relationship in clear perspective
- Practical reviews covering drug use in particular 'at-risk' patient groups to achieve optimal outcomes
- Concept reviews covering issues in pharmacovigilance, risk minimisation and medication error prevention
- Original research articles will also be considered for publication.

All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.

Editor: Rosie Stather

Publication Manager: June B. Hearne

Editorial Office and Inquiries: Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. Information on the preparation of manuscripts will be provided to authors.

E-mail: drugsafety@adis.co.nz <http://www.adis.com/drugsafety>

Drug Safety (ISSN 0114-5916) is published as 1 volume with 15 issues by Adis International Limited. Annual 2003 institutional subscription price: \$US1725. Personal subscription rate: \$US195. For 2003, all subscriptions to Adis titles will include electronic access at no extra cost. (Further subscription information is given at the back of each issue.)

Policy Statement: Although great care has been taken in compiling the content of this publication, the publisher and its servants are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not necessarily reflect the views of the Publisher, Editor or Editorial Board.

Copyright: © Adis Data Information BV 2003. All rights reserved throughout the world and in all languages. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic, including photocopying, recording, or through an information storage and retrieval system, without the written permission of the copyright holder.

The appearance of the code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for the personal or internal use of specific clients. This consent is given provided that the fee of \$US30 per copy is paid directly to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, Massachusetts 01923, USA, for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

Safety and Tolerability Profiles of Intranasal Antihistamines and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis

Rami Jean Salib and Peter Hugo Howarth

Respiratory Cell and Molecular Biology, Faculty of Medicine, Southampton General Hospital, Southampton, United Kingdom

Contents

Abstract	864
1. Intranasal Antihistamines: Historical Perspective	866
2. Levocabastine	866
2.1 General Overview	866
2.2 Tolerability and Safety Profile	867
2.3 Specific Safety and Tolerability Issues	869
2.3.1 Local Tolerability	869
2.3.2 CNS Effects	869
2.3.3 Cardiovascular Effects	869
2.3.4 Drug Interactions	869
2.3.5 Use in Pregnancy	870
2.3.6 Other Effects	870
3. Azelastine	870
3.1 General Overview	870
3.2 Tolerability and Safety Profile	871
3.3 Specific Safety and Tolerability Issues	872
3.3.1 CNS Effects	872
3.3.2 Cardiovascular Effects	872
3.3.3 Use in Pregnancy	873
3.3.4 Other Effects	873
4. Intranasal Corticosteroids	873
4.1 General Overview	873
4.2 Pharmacokinetic Considerations	874
4.3 Tolerability and Safety Profile	877
4.3.1 Local Effects	877
4.3.2 Effects on Hypothalamic-Pituitary Adrenal Axis and Growth	877
4.3.3 Other Systemic Effects	879
4.3.4 Use in Pregnancy	879
5. Specific Corticosteroids	879
5.1 Beclomethasone	879
5.2 Budesonide	880
5.3 Ciclesonide	881
5.4 Flunisolide	881
5.5 Fluticasone Propionate	881

5.6 Mometasone	883
5.7 Triamcinolone	883
6. Specific Safety and Tolerability Considerations	884
6.1 Paediatric Population	884
6.2 Pregnancy	884
6.3 The Elderly	885
7. Conclusion	885

Abstract

Intranasal corticosteroids and intranasal antihistamines are efficacious topical therapies in the treatment of allergic rhinitis. This review addresses their relative roles in the management of this disease, focusing on their safety and tolerability profiles. The intranasal route of administration delivers drug directly to the target organ, thereby minimising the potential for the systemic adverse effects that may be evident with oral therapy. Furthermore, the topical route of delivery enables the use of lower doses of medication. Such therapies, predominantly available as aqueous formulations following the ban of chlorofluorocarbon propellants, have minimal local adverse effects.

Intranasal application of therapy can induce sneezing in the hyper-reactive nose, and transient local irritation has been described with certain formulations. Intranasal administration of corticosteroids is associated with minor nose bleeding in a small proportion of recipients. This effect has been attributed to the vasoconstrictor activity of the corticosteroid molecules, and is considered to account for the very rare occurrence of nasal septal perforation. Nasal biopsy studies do not show any detrimental structural effects within the nasal mucosa with long-term administration of intranasal corticosteroids. Much attention has focused on the systemic safety of intranasal application. When administered at standard recommended therapeutic dosage, the intranasal antihistamines do not cause significant sedation or impairment of psychomotor function, effects that would be evident when these agents are administered orally at a therapeutically relevant dosage.

The systemic bioavailability of intranasal corticosteroids varies from <1% to up to 40–50% and influences the risk of systemic adverse effects. Because the dose delivered topically is small, this is not a major consideration, and extensive studies have not identified significant effects on the hypothalamic-pituitary-adrenal axis with continued treatment. A small effect on growth has been reported in one study in children receiving a standard dosage over 1 year, however. This has not been found in prospective studies with the intranasal corticosteroids that have low systemic bioavailability and therefore the judicious choice of intranasal formulation, particularly if there is concurrent corticosteroid inhalation for asthma, is prudent. There is no evidence that such considerations are relevant to shorter-term use, such as in intermittent or seasonal disease.

Intranasal therapy, which represents a major mode of drug delivery in allergic rhinitis, thus has a very favourable benefit/risk ratio and is the preferred route of administration for corticosteroids in the treatment of this disease, as well as an important option for antihistaminic therapy, particularly if rapid symptom relief is required.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.